Short Integrative And Neurocognitive Therapy For Young Adults With Borderline Personality Disorder

Last updated: April 11, 2025
Sponsor: Centre Hospitalier Universitaire de Nīmes
Overall Status: Active - Recruiting

Phase

N/A

Condition

Borderline Personality Disorder

Schizotypal Personality Disorder (Spd)

Mood Disorders

Treatment

SINTYA

Clinical Study ID

NCT05913544
NIMAO/2022-1/CE-01
  • Ages 16-25
  • All Genders

Study Summary

Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale.

  • High BPD severity level: ZAN-BPD (score ≥ 18/36).

  • Understand, write and read French.

  • Be able to understand the nature, purpose and methodology of the study and agree tocooperate during evaluations.

  • Have signed the informed consent.

  • For minor patients, have signed the parental consent by at least one holder ofparental authority.

Exclusion

Exclusion Criteria:

  • Refusal to participate.

  • Existence of a neurological pathology or cerebral sequelae of organic origin whichcould affect neurocognitive performance.

  • Intelligence quotient < 70.

  • Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7).

  • Previous or current participation in specific psychotherapy for BPD.

  • Subject deprived of liberty (by judicial or administrative decision) and/orprotected by law.

  • Inclusion in another study including psychotherapy for the duration of the study.

  • Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinicaltrials) for the entire duration of the study.

  • Subject in period of exclusion from another research protocol.

Study Design

Total Participants: 74
Treatment Group(s): 1
Primary Treatment: SINTYA
Phase:
Study Start date:
November 08, 2023
Estimated Completion Date:
September 30, 2026

Connect with a study center

  • CHU de Nîmes

    Nîmes,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.